ANI Pharmaceuticals Raises FY23 Net Revenue Guidance To $425M-$445M From $385M-$410M, Vs. Consensus Of $406.41M
Portfolio Pulse from Benzinga Newsdesk
ANI Pharmaceuticals has increased its FY23 net revenue guidance to $425M-$445M, up from the previous $385M-$410M, surpassing the consensus of $406.41M. The company also raised its FY23 adjusted non-GAAP EBITDA guidance to $115M-$125M from the earlier $97M-$107M.
August 09, 2023 | 10:55 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ANI Pharmaceuticals has raised its FY23 net revenue and EBITDA guidance, which is likely to positively impact its stock price.
Companies often see a rise in their stock price when they raise their revenue and EBITDA guidance, as it indicates better-than-expected future performance. Given that ANI Pharmaceuticals' new guidance surpasses the consensus, it's likely that the stock price will react positively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100